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SummAry
Periodic and spontaneous nosebleed is the most common clinical manifestation of hereditary haemorrhagic telangiectasia (hhT), present 
in 95% of patients suffering from this syndrome. The purpose of this retrospective study was to evaluate the effectiveness and safety of 
diathermocoagulation of telangiectasia on the nasal mucosa with a diode laser in the treatment of epistaxis in patients with hhT. From 
2005 to 2010, 24 patients diagnosed with hhT and with mild-severe nosebleed were treated in our hospital with diode laser. Patients were 
given a pre- and post-operation evaluation questionnaire to determine the frequency and severity of nosebleed, the recurrence-free period 
of time after treatment and quality of life. We compared the pre- and post-operation haemoglobin values three months after the last treat-
ment. After treatment, a decrease in the weekly frequency and entity of nosebleed was observed, together with substantial improvement in 
the quality of life and an increase in haematic haemoglobin. Diode laser treatment of telangiectasia on nasal mucosa represents a valuable, 
safe, effective and repeatable therapeutic option in treating mild and severe nosebleed, and it is associated with improvement in quality of 
life from psychological, social and clinical points of view. 
Key WorDS: Epistaxis • HHT • Diathermocoagulation • Diode laser • Nasal endoscopy • Quality of life • Haemoglobin • Psychological 
functionality
riASSunTo
L’epistassi spontanea e ricorrente è la più comune manifestazione clinica della teleangectasia emorragica ereditaria (HHT), presentandosi 
infatti nel 95% dei pazienti affetti dalla malattia. Lo scopo di questo studio retrospettivo è stato quello di valutare la validità e la sicu-
rezza della diatermocoagulazione delle teleangectasie mucose nasali con laser a diodi nel trattamento delle epistassi dei pazienti affetti 
da teleangectasia emorragica ereditaria. Dal 2005 al 2010, 24 pazienti con diagnosi certa di HHT e con epistassi di grado moderato e 
severo sono strati trattati nella nostra U.O. con laser a diodi. I pazienti sono stati sottoposti ad un questionario di valutazione pre- e post-
operatoria per determinare la frequenza e l’entità delle epistassi, il tempo libero da recidiva in seguito al trattamento e la qualità della vita. 
Sono stati confrontati i valori pre- e post-operatori di emoglobina a distanza di tre mesi dal trattamento. In seguito al trattamento abbiamo 
riscontrato una riduzione della frequenza e dell’entità settimanali delle epistassi, un sostanziale miglioramento della qualità della vita dei 
pazienti e un aumento della concentrazione ematica di emoglobina. Il trattamento con laser a diodi delle teleangectasie mucose nasali 
rappresenta una valida, sicura, efficace e ripetibile opzione terapeutica in caso di epistassi di grado moderato e severo, consentendo di 
migliorare sia da un punto di vista psicologico che sociale oltre che clinico la qualità della vita dei pazienti trattati. 
PArole ChiAve: Epistassi • HHT • Diatermocoagulazione • Laser a diodi • Endoscopia nasale • Qualità della vita • Emoglobina • 
Funzionalità psicologica
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Introduction
hereditary haemorrhagic telangiectasia (hhT) or rendu-
osler-Weber syndrome is a rare genetic disease with au-
tosomal dominant inheritance characterized by an angio-
genesis disorder that consists of vascular malformations 
in mucocutaneous tissues, internal organs and the central 
nervous system. in 1896, rendu described this syndrome 
for the first time, defining it as a hereditary syndrome 
characterized by nosebleed and red-violescent cutaneous 
lesions, different from haemophilia. later on, osler and 
Weber defined the clinical aspects of this syndrome. The 
prevalence of hhT ranges from 1:5000 to 1:8000 cases 1. 
This syndrome equally affects males and females without 
racial or ethnic preference.
Angiodysplasia, typical of hhT, can be distinguished in 
arteriovenous malformations or Avm, when large calibre Diode laser in the treatment of hhT-related epistaxis
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Table I. Pre- and post-operation assessment questionnaire in patients with HHT-associated epistaxis (non-validated questionnaire).
PRE- AND POST-OPERATION ASSESSMENT QUESTIONNAIRE IN PATIENTS WITH HHT-RELATED EPISTAXIS
1) Before surgery, how many times a week did you have epistaxis?
• 0-1
• 2-4
• 5-6
• More than 6
• Many times a day
2) Before surgery, how severe was the nosebleed?
• Dripping
• Mild
• Copious
• Gushing
3) Before surgery, how did you consider your epistaxis?
• Very mild
• Mild
• Moderate
• Severe
• Life-threatening
4) After surgery, how long have you been free from epistaxis?
• Within one month
• 1-2 months
• 3-4 months
• More than 4 months
5) Since epistaxis started again, how many episodes have you experienced?
• 0-1/week
• 2-4/week
• 5-6/week
• More than 6/week
• Many times a day
6) Since epistaxis started again, how severe is the nosebleed?
• Dripping
• Mild
• Copius
• Gushing
7) How do you qualify your epistaxis compared to that before the operation?
• Much worse
• Worse
• Equivalent
• Better
• Much better
8) Before surgery, how do you define your life-quality choosing on a scale of 1 (poor) to 7 (excellent)?
Poor Excellent
1 2 3 4 5 6 7
9) After surgery, how do you define your life-quality choosing on a scale of 1 (poor) to 7 (excellent)?
Poor Excellent
1 2 3 4 5 6 7
10) Was your quality of life improved by laser diode treatment, even if temporarily?
• No, it went worse
• No, it did not change
• Yes, briefly
• Yes, for a long time
11) Was the treatment useful?
• No
• Yes, briefly
• Yes, absolutely
12) On a scale of 1 (poor) to 7 (excellent), how do you define your quality of life at present?
Poor Excellent
1 2 3 4 5 6 7m.l. Fiorella et al.
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vessels are affected, and in telangiectasias, when small 
calibre vessels are affected. The arteriovenous malforma-
tions may be present at the cerebral, hepatic, gastroen-
teric and pulmonary levels. Telangiectasias can be present 
at the mucocutaneous level as skin-deep points or star-
shaped red-violescent dilations, single or multiple, local-
ized in different body areas including the lips, tongue, pal-
ate, fingers, face, conjunctiva, torso, arms, nail bed, and 
above all, nasal mucosa.
The most common symptom is epistaxis, which is spon-
taneous and frequently recurrent, and sometimes is so se-
vere as to require iron administration and several blood 
transfusions due to the severe degree of anaemia conse-
quent to bleeding. The onset of recurrent nosebleed can 
occur before the age of 10 years, progressively increasing 
in frequency and severity in the second decade, with a 
major rate in the fourth and fifth decades 2.
Therefore, diagnosis relies on anamnestic data and targets 
defined Curaçao criteria, established in June 1999 by the 
Scientific Advisory Board of the hhT Foundation inter-
national inc.: spontaneous and recurrent nosebleed; mul-
tiple telangiectasias at lips, oral cavity, fingers and nose; 
visceral arteriovenous malformations; positive family an-
amnesis (first-degree siblings diagnosed with hhT, cor-
responding to the above-mentioned criteria). Diagnosis of 
hhT is certain if three criteria are met; it is possible or 
suspect if two criteria are met; it is unlikely if less than 
two criteria are met.
At present, there are no curative or preventative treatments 
specific for hhT, and it is only possible to intervene with 
a “symptomatic” approach by adopting different thera-
peutic choices on the basis of symptom severity.
The present report describes a case-series of patients suf-
fering from hhT, with recurrent and spontaneous epistaxis 
and undergoing diathermocoagulation with a diode laser 
during nasal endoscopy at the otolaryngology operative 
unit of the university of Bari. The goals intended for this 
retrospective study are: long- and short-term evaluation 
of post-operative clinical outcome focused on the recur-
rence-free period, frequency and intensity of epistaxis, 
change  in  haemoglobin  haematic  concentration,  global 
evaluation of social and psychological functionality and 
quality of life before treatment compared to the peri- and 
post-operative phases.
Materials and methods
We  collected  data  concerning  patients  with  hhT  and 
spontaneous and recurrent epistaxis over the period from 
october 2005 to December 2010 in a retrospective man-
ner. Patients were treated with diathermocoagulation us-
ing a diode laser (Ceralas D15/810 nm Biolitec) during 
rigid  nasal  endoscopy  under  general  anaesthesia.  The 
diode laser wavelengths are selectively absorbed by hae-
moglobin, allowing the coagulation of telangiectasias on 
nasal mucosa without damaging the vessel wall or the 
mucosal coating epithelium 2. Data concerning treatments 
and clinical outcome were completed by the results of a 
pre- and post-operation evaluation questionnaire (Table 
i) submitted to patients by telephone interview. We also 
compared  the  pre-operative  haemoglobin  values  to  the 
post-operation values three months after the last treat-
ment; statistical analysis was performed using a two-end-
ed Student’s t-test, with statistical significance set at p < 
0.05. A total of 24 patients diagnosed with hhT accord-
ing to Curaçao criteria and with mild and severe epistaxis 
were included (15 males [62.5%], 9 females [37.5%]), 6 
underwent a second treatment for a total of 30 interven-
tions. The interval between the repeated treatments was 
calculated over 16 months (range 3 to 40 months). We did 
not observe any peri- or post-operative complications. Pa-
tient age ranged from 21-70 years, with an average of 52.5 
years. The most represented age range, within the case se-
ries of this study, was the fourth and sixth decades (75%; 
n = 18). All treatments were carried out on patients that 
were haemodynamically stable. Among the 24 patients 
treated, 4 (16.6%) were missing at follow-up (2 males and 
2 females), one of whom underwent a second treatment. 
For  this  reason,  functional-clinical  outcome  evaluation 
was made on 20 patients (13 males and 7 females). The 
clinical outcome evaluation questionnaire was performed 
to detect not only the present clinical condition of patients, 
but also psychological and social functionality, assessing 
the quality of life over the pre- and post-operative period 
in the short- and long-term.
Results
After diode laser treatment, improvement in symptoms 
was observed, expressed as an increase in the number of 
patients having one or no bleeding event per week com-
pared to the period before intervention (from 5% to 40%; 
from 1 to 8 patients) (Fig. 1), and a decrease (46.6%) in 
the number of patients reporting copious nosebleed (from 
15 to 8) (Fig. 2). 40% of treated patients (n = 8) did not 
Fig. 1. Weekly frequency of epistaxis: in dark grey pre-intervention; in light 
grey post-intervention.Diode laser in the treatment of hhT-related epistaxis
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experience any recurrence for more than 4 months after 
treatment (range 6-8 months); 35% (n = 7) had a recur-
rence within one month, although showing a decrease in 
both frequency and intensity (Fig. 3).
on a scale of 1 to 7, where 1 corresponds to poor and 7 to 
excellent quality of life, half of patients (n = 10) defined 
their quality of life very good or even excellent after treat-
ment, while none of them had stated this prior to treat-
ment (Fig. 4). Photocoagulation of nasal telangiectasias 
by diode laser was considered useful over time by 75% of 
patients (n = 15).
A reliable and objective factor for assessment of im-
provement of symptoms is the concentration of periph-
eral venous blood haemoglobin, expressed in g/dl, since 
it  compares  patient  conditions  before  and  after  inter-
vention. Before treatment, the 20 patients had an aver-
age haemoglobin value of 11.75 g/dl (range 8-15.7 g/
dl), which at three months after treatment was 14.04 g/
dl (range 11-16 g/dl) (Fig. 5). Comparison of the mean 
pre- and post-intervention values using Student’s t-test 
affirmed that this difference was statistically significant 
(p < 0.05).
Discussion
hhT is a genetic disease where an angiogenesis disorder 
reveals itself as telangiectasias and arteriovenous malfor-
mations of mucocutaneous tissues, internal organs and 
the central nervous system. epistaxis, due to telangiecta-
sias on the nasal mucosa, is the most common symptom. 
The severity of bleeding differs from patient to patient, 
and some may need frequent hospitalization and blood 
transfusions; all this substantially affects the quality of 
life. The most suitable treatment of nosebleed requires a 
non-invasive approach that can be repeated and eliminate 
possible  iatrogenic  damages  of  the  lesioned  mucosa 3. 
Several  therapeutic  strategies  have  been  proposed,  but 
none  are  reported  to  be  without  side-effects  or  defini-
tive over a long period of time. The proposed treatments 
can be distinguished in medical and surgical approaches. 
The former include hormonal and anti-hormonal thera-
pies based on oestrogens, progesterone, androgens and 
tamoxifene 4, administration of antifibrinolytic agents such 
as aminocaproic acid and tranexamic acid 5, as well as the 
use of monoclonal antibody bevacizumab whose target is 
vegF 6 7. The latter include endovascular embolization of 
the internal maxillary artery 8, septodermoplasty 9, modi-
fied young’s technique 10 (anterior closure of nasal pits), 
microdebridement 11, bipolar electrocautery 12, photocoag-
ulation using different types of laser (pulsed dye 13 14, Co2, 
nd:yAg 15-17, argon 18 19, KTP 20 21, diode). As an alternative 
to young’s technique, the use of a removable silastic nasal 
obturator has been proposed 22.
Fig. 2. Severity of epistaxis: in dark grey pre-intervention; in light grey post-
intervention.
Fig. 3. Recurrence-free period after treatment.
Fig. 4. Quality of life: in dark grey pre-intervention; in light grey post-in-
tervention.
Fig. 5. Comparison between pre- and post-intervention average haemo-
globin values expressed in g/dl.m.l. Fiorella et al.
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over the last 30 years, laser treatments have been very suc-
cessful and can be considered a valid choice in treatment of 
mild and severe epistaxis in patients with hhT. The recur-
rent feature of bleeding requires the possibility of carrying 
out repeated and specific treatments without damaging the 
nasal mucosa and without complications. lasers act spe-
cifically on the vascular target, thanks to the capability of 
the emitted rays to be absorbed by specific components, 
such as haemoglobin, obtaining photocoagulation of tel-
angiectasias without any damage to vessel walls and the ep-
ithelial coating; moreover, this technique is not associated 
with peri- and post-operative complications. These features 
make the laser treatment repeatable, when needed.
in our case series, similar to literature data 2, we found an 
increase of hhT-related epistaxis following the fourth 
decade of life. of 24 patients who underwent diather-
mocoagulation by diode laser, 6 (25%) had recurrences 
that needed a second treatment after an average of 16 
months from the first. The therapeutic strategy exam-
ined cannot be considered definitive, due to the recur-
rent feature of telangiectasias, but it has the advantage 
of being repeatable and it has no long-term peri- or post-
operative complications and is well tolerated by patients. 
The repeatability, absence of complications and its level 
of tolerability make this procedure a valuable and safe 
therapeutic choice.
in our case series, patients underwent an operation under 
general anaesthesia, in order to control any possible intra-
operative bleedings that would otherwise require treatment 
withdrawal and nasal tamponage. literature data confirms 
the use of general anaesthesia in most cases 13 15-21 due to 
the need for a safe procedure, considering that many pa-
tients will have anaemia.
The effectiveness of treatment is demonstrated by the in-
crease in patients with one or no bleeding event per week, 
compared  to  pre-operative  values  (from  5%  to  40%), 
though some patients still experience more bleeding events 
per week (50% pre-operative and 40% post-operative); in 
the last occurrence, patients were referred for septodermo-
plasty. This result cannot be due to a procedure failure, but 
to the recurrent feature of telangiectasias and the severity 
of the phenotype in those patients. As for the severity of 
bleeding, it should be highlighted that there was a substan-
tial decrease in the number of patients reporting copious 
bleedings, by 46.6%. These results are important because 
the severity and frequency of epistaxis may endanger the 
quality of life from social and employment points of view. 
For this reason, the purpose of treatment should be to de-
crease the frequency and severity of bleeding events, since 
it is unable to stop them definitively considering the recur-
rent feature of telangiectasias. half of patients defined their 
quality of life as very good or excellent after diode laser 
treatment, whereas none expressed this prior to treatment. 
This shows that chosen procedure is effective in improv-
ing psychological and social status, in addition to symp-
tomatology. 40% of patients did not have any recurrence 4 
months after the treatment, whereas 35% had a recurrence 
within one month, showing nonetheless a decrease in the 
frequency and severity of bleeding events and making a 
second treatment unnecessary at least until the end of the 
study period. indeed, photocoagulation of telangiectasias 
by diode laser was useful over time in 75% of patients. At 
present, their quality of life has remarkably improved, con-
firming the effectiveness of treatment.
The increase in the average haemoglobin concentration 3 
months after the operation during follow-up was statisti-
cally significant. The haemoglobin value is strictly linked 
to the level of anaemia whose cause is blood loss. We 
chose our patients considering the absence of gastroen-
teric bleeding, another event causing anaemia. in our case 
series, a considerable decrease in frequency and severity 
of  bleedings  helped  to  improve  the  haemato-chemical 
picture, as well as anaemia of patients. in clinical prac-
tice, this means fewer admissions and blood transfusions, 
reflecting the improved clinical and social condition of 
patients. The increase in haemoglobin concentration con-
firms the validity of treatment by diode laser in control-
ling hhT-associated epistaxis.
Photocoagulation of mucosal lesions using a diode laser 
has demonstrated an efficacy, in some series, comparable 
to a KTP laser 20 21 or nd:yAg laser 16 17, considering im-
provement in symptoms, relapse free-time, safety and ab-
sence of complications.
Furthermore, our results compare positively to series in 
which argon laser treatment had to be repeated in all pa-
tients 18 or was not possible because of severe epistaxis 19, 
and to other series using treatment with nd:yAg laser in 
which mild or moderate epistaxis required two or more 
re-treatments 15. in fact, our study has highlighted the ef-
fectiveness of diode laser treatment of moderate and se-
vere epistaxis, and only six (20%) re-treatments were per-
formed during the follow-up period.
our results show the effectiveness even if compared with 
series in which patients, treated with a pulsed dye laser, 
obtained benefits only after an average of three courses 
of treatment 13. one case report 14, in which treatment was 
performed by pulsed dye laser, had shown a limit related 
to the implementation of the procedure under local anaes-
thesia in an outpatient setting, with the consequence of 
an ineffective post-operative follow-up, affecting the pos-
sibility of control of short-term complications, unlike our 
patients who were hospitalized and followed more close-
ly. however, it should be underlined that in our series no 
short-term complications were observed.
Conclusions
The  procedure  of  diathermocoagulation  by  diode  laser 
in treatment of nasal telangiectasias in patients suffering 
from hhT is an effective therapeutic method with a good Diode laser in the treatment of hhT-related epistaxis
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safety profile. it acts selectively on vascular tissues without 
damaging the surrounding epithelium, has no side-effects 
and no peri- or post-operation morbidity, is well tolerated 
and can be repeated when needed. The technique contrib-
uted to reducing the frequency and severity of bleedings, 
thus improving the quality of life from clinical, social and 
psychological points of view.
Further prospective studies with a longer follow-up and 
a larger number of patients will be necessary to better 
understand the actual effectiveness of diode laser in the 
treatment of hhT-associated epistaxis.
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